Last reviewed · How we verify
Bisoprolol versus Nebivolol
Both bisoprolol and nebivolol are beta-1 selective adrenergic receptor antagonists that reduce heart rate and blood pressure by blocking sympathetic nervous system signaling in the heart.
Both bisoprolol and nebivolol are beta-1 selective adrenergic receptor antagonists that reduce heart rate and blood pressure by blocking sympathetic nervous system signaling in the heart. Used for Hypertension, Heart failure with reduced ejection fraction, Angina pectoris.
At a glance
| Generic name | Bisoprolol versus Nebivolol |
|---|---|
| Sponsor | Clinical Hospital Center Zemun |
| Drug class | Beta-1 selective adrenergic receptor antagonist (cardioselective beta-blocker) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Bisoprolol and nebivolol are cardioselective beta-blockers that preferentially inhibit beta-1 adrenergic receptors on cardiac tissue, decreasing heart contractility and heart rate. Nebivolol has additional vasodilatory properties mediated through nitric oxide release, which may provide additional cardiovascular benefits beyond standard beta-blockade. Both agents are used to manage hypertension and heart failure by reducing cardiac workload and improving diastolic function.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Angina pectoris
- Post-myocardial infarction management
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Hypotension
- Headache
- Dyspnea
Key clinical trials
- Echocardiographic Study of a Single Dose Bisoprolol Versus Nebivolol in Healthy Subjects (PHASE4)
- Catheter Ablation Versus Medical Rate Control for Atrial Fibrillation in Patients With Heart Failure (NA)
- Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bisoprolol versus Nebivolol CI brief — competitive landscape report
- Bisoprolol versus Nebivolol updates RSS · CI watch RSS
- Clinical Hospital Center Zemun portfolio CI